---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-065786"
form_type: "8-K"
ticker: "KRRO"
cik: "0001703647"
company_name: "Korro Bio, Inc."
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T08:28:26.988539+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Korro Q1 net loss $23.4M; workforce reduction of 20%, cash runway into 2027

## Summary
- Net loss $23.4M vs $19.6M YoY; collaboration revenue $2.6M from Novo Nordisk.
- Cash, cash equivalents and marketable securities $139.0M, expected to fund operations into 2027.
- Workforce reduction of approximately 20%; one-time restructuring charges ~$1.2M in Q2 2025.
- Phase 1/2a REWRITE trial interim readout for KRRO-110 expected H2 2025; trial completion in 2026.
- Expect to nominate second development candidate in 2025; Novo Nordisk cardiometabolic collaboration ongoing.

## SEC filing metadata
- accession: 0000950170-25-065786
- form_type: 8-K
- ticker: KRRO
- cik: 0001703647
- company_name: Korro Bio, Inc.
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703647/000095017025065786/0000950170-25-065786-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703647/000095017025065786/krro-20250507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-065786
- JSON: https://secwatch.observer/filing/0000950170-25-065786.json
- Plain text: https://secwatch.observer/filing/0000950170-25-065786.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.